Exploiting cellular pathways to develop new treatment strategies for AML

Amir T. Fathi, Steven Grant, Judith Karp

Research output: Contribution to journalArticle

Abstract

The standard approaches to the treatment of acute myeloid leukemia (AML) have been predominantly based on cytarabine and anthracyclines. Yet, the outcomes associated with AML continue to be poor, especially for those patients who are older or carry higher-risk disease. In recent years, extensive research has led to the development and study of novel agents which target AML by diverse and varied mechanisms. Among these are targeted therapeutics such as kinase inhibitors and oligonucleotide constructs. These aim to suppress the production or activity of proteins, such as FLT3 and BCL2, among others, and thus disrupt related signaling cascades essential for leukemogenesis and proliferation. In addition, other agents like flavopiridol appear to target the myeloid blast by various mechanisms including suppression of cyclin-dependent kinases and interference with nucleotide synthesis. Another class of novel therapies includes inhibitors of histone deacetylase, which cause growth arrest and apoptosis through histone acetylation and resultant conformational changes. Clinical trials are now studying these and other agents alone and in combination with traditional cytotoxic therapies, with some encouraging results. In this review, we aim to provide a summary of the preclinical and clinical investigations of selected promising agents currently under study.

Original languageEnglish (US)
Pages (from-to)142-150
Number of pages9
JournalCancer Treatment Reviews
Volume36
Issue number2
DOIs
StatePublished - Apr 2010

Fingerprint

Acute Myeloid Leukemia
alvocidib
Histone Deacetylase Inhibitors
Cyclin-Dependent Kinases
Anthracyclines
Cytarabine
Therapeutics
Acetylation
Oligonucleotides
Histones
Phosphotransferases
Nucleotides
Clinical Trials
Apoptosis
Growth
Research
Proteins

Keywords

  • Acute myeloid leukemia
  • Flavopiridol
  • FLT3
  • HDAC inhibitor
  • PARP
  • Targeted therapies

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Exploiting cellular pathways to develop new treatment strategies for AML. / Fathi, Amir T.; Grant, Steven; Karp, Judith.

In: Cancer Treatment Reviews, Vol. 36, No. 2, 04.2010, p. 142-150.

Research output: Contribution to journalArticle

Fathi, Amir T. ; Grant, Steven ; Karp, Judith. / Exploiting cellular pathways to develop new treatment strategies for AML. In: Cancer Treatment Reviews. 2010 ; Vol. 36, No. 2. pp. 142-150.
@article{ee0bcdf9e09741b0b659554a2ee267a5,
title = "Exploiting cellular pathways to develop new treatment strategies for AML",
abstract = "The standard approaches to the treatment of acute myeloid leukemia (AML) have been predominantly based on cytarabine and anthracyclines. Yet, the outcomes associated with AML continue to be poor, especially for those patients who are older or carry higher-risk disease. In recent years, extensive research has led to the development and study of novel agents which target AML by diverse and varied mechanisms. Among these are targeted therapeutics such as kinase inhibitors and oligonucleotide constructs. These aim to suppress the production or activity of proteins, such as FLT3 and BCL2, among others, and thus disrupt related signaling cascades essential for leukemogenesis and proliferation. In addition, other agents like flavopiridol appear to target the myeloid blast by various mechanisms including suppression of cyclin-dependent kinases and interference with nucleotide synthesis. Another class of novel therapies includes inhibitors of histone deacetylase, which cause growth arrest and apoptosis through histone acetylation and resultant conformational changes. Clinical trials are now studying these and other agents alone and in combination with traditional cytotoxic therapies, with some encouraging results. In this review, we aim to provide a summary of the preclinical and clinical investigations of selected promising agents currently under study.",
keywords = "Acute myeloid leukemia, Flavopiridol, FLT3, HDAC inhibitor, PARP, Targeted therapies",
author = "Fathi, {Amir T.} and Steven Grant and Judith Karp",
year = "2010",
month = "4",
doi = "10.1016/j.ctrv.2009.12.004",
language = "English (US)",
volume = "36",
pages = "142--150",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Exploiting cellular pathways to develop new treatment strategies for AML

AU - Fathi, Amir T.

AU - Grant, Steven

AU - Karp, Judith

PY - 2010/4

Y1 - 2010/4

N2 - The standard approaches to the treatment of acute myeloid leukemia (AML) have been predominantly based on cytarabine and anthracyclines. Yet, the outcomes associated with AML continue to be poor, especially for those patients who are older or carry higher-risk disease. In recent years, extensive research has led to the development and study of novel agents which target AML by diverse and varied mechanisms. Among these are targeted therapeutics such as kinase inhibitors and oligonucleotide constructs. These aim to suppress the production or activity of proteins, such as FLT3 and BCL2, among others, and thus disrupt related signaling cascades essential for leukemogenesis and proliferation. In addition, other agents like flavopiridol appear to target the myeloid blast by various mechanisms including suppression of cyclin-dependent kinases and interference with nucleotide synthesis. Another class of novel therapies includes inhibitors of histone deacetylase, which cause growth arrest and apoptosis through histone acetylation and resultant conformational changes. Clinical trials are now studying these and other agents alone and in combination with traditional cytotoxic therapies, with some encouraging results. In this review, we aim to provide a summary of the preclinical and clinical investigations of selected promising agents currently under study.

AB - The standard approaches to the treatment of acute myeloid leukemia (AML) have been predominantly based on cytarabine and anthracyclines. Yet, the outcomes associated with AML continue to be poor, especially for those patients who are older or carry higher-risk disease. In recent years, extensive research has led to the development and study of novel agents which target AML by diverse and varied mechanisms. Among these are targeted therapeutics such as kinase inhibitors and oligonucleotide constructs. These aim to suppress the production or activity of proteins, such as FLT3 and BCL2, among others, and thus disrupt related signaling cascades essential for leukemogenesis and proliferation. In addition, other agents like flavopiridol appear to target the myeloid blast by various mechanisms including suppression of cyclin-dependent kinases and interference with nucleotide synthesis. Another class of novel therapies includes inhibitors of histone deacetylase, which cause growth arrest and apoptosis through histone acetylation and resultant conformational changes. Clinical trials are now studying these and other agents alone and in combination with traditional cytotoxic therapies, with some encouraging results. In this review, we aim to provide a summary of the preclinical and clinical investigations of selected promising agents currently under study.

KW - Acute myeloid leukemia

KW - Flavopiridol

KW - FLT3

KW - HDAC inhibitor

KW - PARP

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=77950620888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950620888&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2009.12.004

DO - 10.1016/j.ctrv.2009.12.004

M3 - Article

C2 - 20056334

AN - SCOPUS:77950620888

VL - 36

SP - 142

EP - 150

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 2

ER -